What is it about?
Serous endometrial adenocarcinoma (SEA) and mixed mullerian tumor of the ovary (MMOT) are two rare, highly aggressive tumor entities arising from the mullerian epithelium. Despite their distinct localization, they share many morphological, immunohistochemical and molecular features, including a high frequency of TP53 mutations, loss of hormonal expression and a high-grade serous signature.
Featured Image
Photo by Buddha Elemental 3D on Unsplash
Why is it important?
Their prognosis is unfavorable, largely due to late diagnosis, early dissemination and limited response to standard treatments. Cytoreductive surgery and platinum-based chemotherapy are the mainstays of treatment, although their efficacy remains limited, particularly in TMMO.
Perspectives
Serous endometrial adenocarcinoma (SEA) and mixed Müllerian tumor of the ovary (MMOT), also known as ovarian carcinosarcoma, are two rare but highly aggressive gynecological cancers. ESA accounts for around 10% of endometrial cancers, but is responsible for almost 40% of deaths due to this pathology [1].
Acquire Publications
Read the Original
This page is a summary of: Serous Endometrial Adenocarcinoma (SEA) and Mixed Müllerian Tumor of the Ovary (MMOT): A Report Case, Journal of Case Reports and Medical History, July 2025, Acquire Publications LLC,
DOI: 10.54289/jcrmh2500126.
You can read the full text:
Contributors
The following have contributed to this page
